Document:

Escrow Agreement

 Exhibit 10.104 
  
 Escrow Agreement 
  
 This Escrow Agreement (“Agreement”) among Kendro Laboratory Products PLC and Cryonix, a division thereof (together, “Cryonix”), Agen
Biomedical Limited (“Agen”) and Synbiotics Corporation (“Synbiotics”) is effective on this 5th day of October, 2004 (the “Effective Date”). 
  
 Recitals 
  
 Whereas, Synbiotics has agreed to supply to Agen from time to time certain Biological Materials for the purpose of inclusion in ICT lateral flow
veterinary test kit products, all pursuant to and to the extent authorized by a Settlement Agreement and Mutual Release of Claims dated June 23, 2004 (“Settlement Agreement”). The Settlement Agreement is attached hereto as Exhibit B and is
incorporated herein by reference. For further assurance to Agen, the Settlement Agreement calls for the delivery into this escrow, pursuant to this Escrow Agreement, of the Deposit Cell Lines and other Deposit Materials required by Section 11.1 of
the Settlement Agreement. (Capitalized terms not otherwise defined in this Escrow Agreement shall have the meanings assigned to them in the Settlement Agreement.) 
  
 Whereas, Agen and Synbiotics hereby designate and appoint Cryonix as the escrow agent under this Escrow Agreement. Cryonix
hereby accepts such designation and appointment and agrees to carry out the duties of escrow agent pursuant to the terms and provisions of this Escrow Agreement. Cryonix is not a party to, and is not bound by, any agreement that might be evidenced
by, or might arise out of, any prior or contemporaneous dealings between Synbiotics and Agen other than as expressly set forth herein. 
  
 Whereas, the parties desire that this Escrow Agreement be an agreement supplementary (together with any modification, supplement, or replacement thereof
agreed to by the parties) to the Settlement Agreement pursuant to Title 11 United States Code Section 365(n). 
  
 NOW, THEREFORE, for and in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto, intending to be legally bound hereby, covenant and agree as follows: 
  
 1. Deposit Materials 
  
 (a) Initial Deposit—Synbiotics shall submit the initial Deposit Materials to Cryonix within ten (10) days after the Effective Date. Synbiotics shall complete and deliver with all Deposit Materials a
listing of all Deposit Materials, divided into respective Deposit Categories (as defined in (c) below). Cryonix shall notify Agen within 10 days of receipt of the initial Deposit Materials. The listing itself constitutes Synbiotics proprietary
information and is not to be released to Agen (but such list shall be included and held as part of the Deposit Materials). 
  
 (b) Deposit Material Updates—Synbiotics shall submit updates to the initial Deposit Materials to Cryonix as and when required
by the Settlement Agreement. Synbiotics shall complete and deliver with all updates to the Deposit Materials an amended listing of all Deposit Materials, divided into respective Deposit Categories. Cryonix shall notify Agen within 10 days of
receipt of updates to the Deposit Materials. All references herein to “Deposit Materials” shall include such updates thereto. The listing itself constitutes Synbiotics proprietary information and is not to be released to Agen (but such
list shall be included and held as part of the Deposit Materials). 
  
 (c) Deposit Categories—The initial Deposit Materials, and any updates thereof, shall be defined and designated by Synbiotics into one of four respective groups of Deposit Materials which are specific to
each of the four particular Biological Materials specified in Section 8.1 of the Settlement Agreement and the 

  

 Page 1 of 9 

 
manufacture (or other production) of such Biological Material suitable (as measured by the Specifications, laws and regulations applicable as of the most
recent deposit or update into escrow) for commercialization (“Deposit Categories”). Each Deposit Category’s Deposit Materials must be complete and, in and of itself, meet all of the requirements set forth in the Settlement Agreement
for such particular Biological Material manufacture or commercialization. 
  
 (d) Deposit Material Verification—Upon Agen’s written request and at Agen’s expense, no more than once following a given deposit of any Deposit Materials or any update thereto, Cryonix shall
allow and investigator to be designated by Agen who is reasonably acceptable to Synbiotics (the “Examiner”) to confirm whether the Deposit Materials comply with the requirements of the Settlement Agreement, by permitting the Examiner
(under confidentiality agreement) to examine and to confirm compliance of the Deposit Materials with the requirements of the Settlement Agreement. Cryonix shall report forthwith to Synbiotics and Agen whether the Examiner confirms or declines to
confirm that the Deposit Materials, including also each respective Deposit Category in and of itself, comply with the requirements of the Settlement Agreement; and if the Examiner declines to so confirm then Cryonix shall also report to Synbiotics
(but not to Agen) the details of the deficiency, in order to assist Synbiotics in providing updated Deposit Materials to attempt to cure the deficiency. Without limiting the rights or remedies of Agen under this Agreement or the Settlement
Agreement, the process of this Section 1(d) will thereupon be repeated. Cryonix shall not be liable for any actions taken on the part of the Examiner with regards to the Deposit Materials. 
  
 (e) Storage Conditions—Except to the extent
Cryonix and Agen agree otherwise in writing, Cryonix agrees to store the Deposit Cell Lines within escrow, frozen under the following freezing conditions: Storage in liquid nitrogen at -196°C in a non-segregated LN2 vessel. The storage unit
containing the Deposit Cell Lines will be monitored for temperature every (ten) 10 minutes by a GMP compliant system. Full documentation of temperature, alarm information, maintenance and inventory will be maintained by Cryonix and provided to the
parties on a monthly basis. Cryonix agrees to store the documents within the Deposit Materials in a standard fireproof and secure 4-drawer cabinet. Cryonix’s storage facility will be GMP compliant. The amount and/or type of freezing vessel can
be changed at any time (subject to payment of applicable fees) and no limit exists for the amount of time the Deposit Materials may be stored at Cryonix’s facility. 
  
 (f) Additional Services Included with Storage. The storage service provided by Cryonix hereunder also
include the following: 
  

	 	•	 	Comprehensive monthly reports summarizing temperatures and all inventory transactions 

  

	 	•	 	Automatic Insurance of £10,000.00 per freezer unit/inventory 

  

	 	•	 	Full access during business hours for authorised personnel 

  

	 	•	 	Complete audit of Cryonix SOP’s 

  

	 	•	 	Full maintenance and repairs on all customer owned equipment stored within Cryonix’s facility. 

  
 2. Term 
  
 (a) Termination of Agreement—This Escrow Agreement shall remain in effect until terminated as provided for herein. This Escrow
Agreement may be terminated either by written mutual consent of Synbiotics and Agen or by any party if one of the following occurs: 
  
 i. The Deposit Materials have all been released or returned in accordance with the terms hereof, or 
  
 ii. The Settlement Agreement is terminated in accordance
with its terms or by order of the Court, or 
  
 iii. The occurrence of the event described in Section 10.7(f) of the Settlement Agreement, or 
  
 iv. An order of the Court declaring that this Escrow Agreement is terminated is delivered to Cryonix. 
  

 Page 2 of 9 

 (b) Termination for Non-Payment—In the event that full payment of any or all
fees due to Cryonix under this Escrow Agreement have not been received by Cryonix within 30 days of the date payment is due, Cryonix will notify all parties hereto of the delinquent fees. If the delinquent fees are not received within 30 days of the
delinquency notification, Cryonix shall have the right to terminate this Escrow Agreement. 
  
 3. Fees 
  
 (a) Payment—Upon receipt of the initial Deposit Materials, Cryonix will submit an initial invoice to Agen for the initial indicated amount shown on Exhibit A attached hereto. If payment is not received, Cryonix shall have no
obligation to perform its duties under this Escrow Agreement. Agen agrees to pay to Cryonix all additional fees for services rendered related to this Escrow Agreement as shown on, and at the times specified in, Exhibit A. The fee for any service
that is not expressly covered in Exhibit A shall be reasonably established by Cryonix in advance upon request. All fees are due on the dates specified in Exhibit A and are non-refundable. Subject to Agen’s prior written consent, Cryonix may
reasonably amend Exhibit A at any time upon 60 days’ written notice to Agen and Synbiotics, provided that Cryonix shall not increase any of the fees set forth in Exhibit A more than once per calendar year. 
  
 (b) Currency—All fees are in pounds sterling
(UK) and payment must be rendered in pounds unless otherwise agreed to in advance by Cryonix. 
  
 (c) Late Payment—Any amounts payable by Agen hereunder that remain unpaid after the due date will be subject to a late charge
equal to the lesser of one and one-half percent (1.5%) per month and the maximum rate allowable by law. 
  
 4. Indemnification—With the exception of gross negligence, willful misconduct, material breach of this Escrow Agreement, or intentional
misrepresentation on behalf of Cryonix, Synbiotics and Agen shall, jointly and severally, indemnify and defend, and each shall hold harmless, Cryonix and each of Cryonix’s directors, officers, agents, employees, members and stockholders
(“Cryonix Indemnitees”) absolutely and forever, from and against any and all claims, actions, damages, suits, liabilities, obligations, costs, fees, charges, and any other expenses whatsoever, including reasonable attorneys’ fees and
costs, that may be asserted against any Cryonix Indemnitee in connection with this Escrow Agreement or the performance of Cryonix or any Cryonix Indemnitee hereunder. 
  
 5. Synbiotics’ Representations and Warranties 
  
 Synbiotics represents and warrants to Agen that the Deposit Materials as delivered to Cryonix meet the requirements set
forth in Section 11.1 of the Settlement Agreement, and are viable and fit for their intended purpose under the Settlement Agreement. Synbiotics shall update the Deposit Materials as provided for in the Settlement Agreement, and at the time of each
such update shall make the same representation and warranty to Agen as to the Deposit Materials as updated. 
  
 6. Return of Deposit Materials to Synbiotics—Upon the event described in Section 10.7(f) of the Settlement Agreement, upon the event described
in Section 8.4 of the Settlement Agreement, or upon termination of this Escrow Agreement for any reason other than in the event all Deposit Materials have been released to Agen, Cryonix shall return the Deposit Materials to Synbiotics (other than
those already released to Agen hereunder) via commercial courier to the address of Synbiotics shown in this Escrow Agreement. If two attempts to return Deposit Materials via commercial courier to Synbiotics fail or Synbiotics does not accept the
Deposit Materials, Cryonix shall destroy the Deposit Materials. 
  
 If Section 8.4 of the Settlement Agreement is applicable only to one (or some) of the Deposit Categories, only the Deposit Materials pertaining to such Deposit Cell Category(s) shall be returned to Synbiotics (or destroyed) under this
Section 6. 
  

 Page 3 of 9 

 7. Release of Deposit Materials to Agen 
  
 (a) Release—The Deposit Materials will be
released to Agen only in the event and only to the extent that: 
  
 i. Synbiotics requests Cryonix in writing to effect such release; or 
  
 ii. The release procedure set forth in this Section 7 is followed. The first step in the release procedure shall be that Agen makes
written request to Cryonix (with a copy to Synbiotics as required by the Settlement Agreement) to release to Agen all the Deposit Materials (or, as appropriate, to release all Deposit Materials within one or more specified Deposit Categories) and in
which request Agen must expressly: 
  
 a. Assert
that a Tentative Trigger Event has occurred under the Settlement Agreement; and 
  
 b. Include a detailed specification of the alleged Tentative Trigger Event and the affected Deposit Category(s)); and 
  
 c. Include specific instructions for the delivery of the
Deposit Materials (or, as the case may be, all Deposit Materials within one or more specified Deposit Categories). 
  
 (b) Failsafe Re-Transmission of Agen Request for Release—If the provisions of Section 7(a)(ii) are met, Cryonix shall within
two business days forward a complete copy of Agen’s request to Synbiotics by fax. 
  
 (c) Synbiotics Non-Objection to Release—Synbiotics shall have 20 days after Agen’s delivery of notice to object to Agen
and Cryonix in writing. If after 20 days after Agen’s delivery of notice Cryonix has not received any written objection from Synbiotics, Cryonix shall release the Deposit Materials (or, as the case may be, the Deposit Materials within the
specified Deposit Category(s)) to Agen as instructed by Agen. 
  
 If the alleged Tentative Trigger Event is as defined in Section 11.4 of the Settlement Agreement, the references in this Section 7(c) to “20 days” shall instead be read as “three days.” 
  
 (d) Synbiotics Objection to Release—Should
Synbiotics object before the deadline specified in Section 7(c) above to the request for release by Agen in writing, Cryonix shall notify Agen by fax within two business days of Cryonix’s receipt of said objection and shall notify both parties
that there is a dispute to be resolved. Cryonix shall continue to hold the Deposit Materials (or, as the case may be, the Deposit Materials within the specified Deposit Category(s)) without release pending (i) joint instructions from Synbiotics and
Agen; or (ii) Cryonix’s receipt of an order from the United States District Court for the Southern District of California finding that a Tentative Trigger Event did occur. In the event the foregoing joint instructions or court order so
specifies, Cryonix shall promptly release the applicable Deposit Materials. Cryonix is not entitled to rely on any order of such Court which does not contain such a finding, nor on any order whatever of any other court, tribunal, forum or
governmental authority (except for the order of a court that has assumed jurisdiction over the subject matter of this Agreement from such Court, such as, if applicable, the United States Bankruptcy Court). 
  
 (e) Release Delivery. In the event release is
triggered under this Section 7 as provided above, Cryonix shall promptly release the applicable Deposit Materials and deliver them to Agen to the location designated by Agen (and in accordance with the delivery instructions provided by Agen) under
Section 7(a)(ii) above or otherwise in writing. Agen shall pay the costs of such delivery. 
  
 8. Dispute Resolution—Any dispute or claim arising out of or relating to this Escrow Agreement, or the breach thereof, shall be resolved by the United States District Court for the Southern District of
California. Cryonix hereby consents and agrees to submit to the jurisdiction of the United States District Court for the Southern District of California for purposes of enforcing or otherwise adjudicating disputes regarding the parties’ rights,
obligations and remedies under this Agreement. 
  

 Page 4 of 9 

 9. Confidentiality—Except as otherwise required to carry out its duties under this Escrow
Agreement, Cryonix shall hold in strictest confidence and not permit any third party access to nor otherwise use, disclose, transfer or make available the Deposit Materials (or the Section 1 listings) except as otherwise provided herein, unless
consented to in writing by Synbiotics. 
  
 10. Limitation of
Liability—In performing any of its duties hereunder, Cryonix shall not incur any liability to any party for any damages, losses, or expenses, except for intentional misrepresentation, willful misconduct, material breach of this Escrow
Agreement, or gross negligence on the part of Cryonix, and it shall not incur any liability with respect to any action taken or omitted in reasonable reliance upon any written notice, request, waiver, consent, receipt or other document which Cryonix
in reasonable good faith believes to be genuine. 
  
 11.
Notices—Notices under this Escrow Agreement (and, to the extent they bear on the escrow or this Escrow Agreement, notices under the Settlement Agreement) must be in writing and shall be conclusively deemed to be given (i.e., to be
simultaneously delivered and received) at and only at the times established by the following conventions: (a) if transmitted by overnight courier, on the day the addressee signs an acknowledgement of receipt (or, if such day is not a business day in
the addressee’s jurisdiction, or if the acknowledgement of receipt is signed after business hours on a business day, then on the next business day), (b) if transmitted by fax, on the day received by the addressee with normal
machine-confirmation of successful transmission (or, if such day is not a business day in the addressee’s jurisdiction, or if the transmission/confirmation is after hours on a business day, then on the next business day), and (c) if transmitted
by any other method, then on the day actually received by the addressee at such address (or, if such day is not a business day in the addressee’s jurisdiction, or if the actual receipt is after business hours on a business day, then on the next
business day). All notices must be addressed and sent to the person(s)’ address or fax number as provided below, or to such other address/fax number as a party may have previously given notice of under this Section 11:  
  

							
	 Synbiotics

		
	 Company:
	 	 Synbiotics Corporation

	 Contact:
	 	 Paul Hays
	  	 Title:
	 	 President

	 Address:
	 	 11011 Via Frontera

	 	 	 San Diego, CA 92127

	 Telephone:
	 	 (858) 451-3771
	  	 Fax:
	 	 (858) 451-5719

	 Email:
	 	 paulh@synbiotics.com

	
	 Agen

		
	 Company:
	 	 Agen Biomedical Limited

	 Contact:
	 	 Donald Home
	  	 Title:
	 	 Managing Director

	 Address:
	 	 11 Durbell Street Acacia Ridge, Queensland Australia

	 Telephone:
	 	 +61 7 3370 6300
	  	 Fax:
	 	 +61 7 3370 6370

	 Email:
	 	 info@agen.com.au

	
	 Cryonix

		
	 Company:
	 	 Cryonix

	 Contact:
	 	 Robert Jones
	  	 Title:
	 	 Head of Repository Operations

	 Address:
	 	 Woodside, Bishops Stortford

	 	 	 Herts CM23

	 	 	 United Kingdom

	 Telephone:
	 	 44(0) 1279-827700
	  	 Fax:
	 	 44(0) 1279-827750

	 Email:
	 	 robert.jones@kendro.spx.com

  

 Page 5 of 9 

 12. Miscellaneous 
  
 (a) Counterparts—This Escrow Agreement may be executed in any number of multiple counterparts,
each of which is to be deemed an original, and all of such counterparts together shall constitute one and the same instrument. 
  
 (b) Entire Agreement—This Escrow Agreement (together with the Settlement Agreement, to the extent referenced and/or
incorporated herein) supersedes all prior and contemporaneous letters, correspondences, discussions and agreements among the parties with respect to all matters contained herein, and it constitutes the sole and entire agreement among them with
respect thereto. As between Synbiotics and Agen the Settlement Agreement in its entirety is not superseded. 
  
 (c) Limitation of Effect—This Escrow Agreement pertains strictly to the escrow services provided for herein and does not
modify, amend or affect any other contract or agreement of one or more of the parties. The terms and provisions of the Settlement Agreement shall continue in full force and effect and be binding upon and inure to the benefit of the parties hereto,
their legal representatives, successors and assigns. 
  
 (d) Modification; Waiver—This Escrow Agreement shall not be altered or modified without the express written consent of all parties. Failure at any time to require performance of any of the provisions herein shall not waive or
diminish a party’s right thereafter to demand compliance therewith or with any other provision. Waiver of any default shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in
writing and signed by a duly authorized officer of the party making such waiver. 
  
 (e) Bankruptcy Code—This Escrow Agreement shall be considered an agreement supplementary (together with any modification,
supplement, or replacement thereof agreed to by the parties) to the Settlement Agreement pursuant to Title 11 United States Code Section 365(n). 
  
 (f) Survival of Terms—All obligations of the parties intended to survive the termination of this Escrow Agreement, including
without limitation, the provisions of paragraphs 2 (Term), 4 (Indemnification), 8 (Dispute Resolution), 10 (Limitation of Liability), and 12 (Miscellaneous) shall survive the termination of this Escrow Agreement for any reason. 
  
 (g) Governing Law—This Escrow Agreement shall be
governed by the laws of the state of California, as applied to contracts between California residents entered into and performed wholly within California. 
  
 (h) Time of the Essence—Time is of the essence in this Escrow Agreement. 
  
 (i) Successors and Assigns—This Escrow Agreement
shall be binding upon and inure to the benefit of the successors and assigns of the parties, provided, however, that Agen and Synbiotics shall have no right to assign any rights or obligations hereunder or with respect to the Deposit Materials
except as permitted with respect to assignment of such party’s rights under the Settlement Agreement. 
  
 (j) Severability.—In the event any provision of this Escrow Agreement shall be determined to be invalid, illegal or
unenforceable, such provision shall be severable from the remainder of the Escrow Agreement, and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
  
 (k) Good Manufacturing Practice/Good Laboratory Practice
Compliance (GMP/GLP).—Cryonix shall ensure that all services provided as part of this Escrow Agreement comply with all applicable governing laws, rules and regulations, including but not limited to those relating to Good Manufacturing
Practices (GMP), Good Laboratory Practices and any comparable regulations and guidelines. 
  
 (Signatures are on following page. Remainder of the page intentionally left blank.) 
  

 Page 6 of 9 

 IN WITNESS WHEREOF, the parties have executed this Escrow Agreement by and through their duly authorized
agents as of the Effective Date. 
  
  

					
	Synbiotics Corporation
			
	 Signature:
	 	 /s/    PAUL R. HAYS        

	 	 18.Nov.’04

	 Name:
	 	Paul R. Hays	 	 
	 Title:
	 	President & COO	 	 
	
	Agen Biomedical Limited
			
	 Signature:
	 	 /s/    DONALD HOME        

	 	 
	 Name:
	 	Donald Home	 	 
	 Title:
	 	Managing Director	 	 
	
	Cryonix
			
	 Signature:
	 	 /s/    ROBERT JONES        

	 	 
	 Name:
	 	Robert Jones	 	 
	 Title:
	 	Head of Repository Operations	 	 
		
	 Date: 3.Nov.2004
	 	 
	
	Kendro Laboratory Products PLC
			
	 Signature:
	 	 /s/    C. LAING        

	 	 
	 Name:
	 	C. Laing	 	 
	 Title:
	 	Operations Director	 	 
		
	 Date: 3/11/04
	 	 

  

 Page 7 of 9 

 Exhibit A 
  

Schedule of Fees 
  
 1. Storage of 10-15 vials containing Deposit Cell Lines in non-segregated LN2 vessel: 
  
 £ 12.00 (twelve pounds) per month* 
  
 2. Storage of Documents within Deposit Materials in fireproof 4-drawer cabinet: 
  
 £ 50.00 (fifty pounds) per month* 

 * Items 1 and 2 to be invoiced and paid on an annual basis, in advance for each one year period. 
  
 3. Receiving Charges for Subsequent Deposits—initial receipt of Deposit
Materials is at no charge (includes receipt, inspection, and placement of Deposit Materials into unit): 
  
 £ 30.00 (thirty pounds) per receipt 
  
 4. Shipping Services (Domestic and International Shipping)—Includes retrieval and packaging of Deposit Materials for shipment using shipping material
to maintain Deposit Cell Line storage temperatures and to comply with all international shipping regulations to include hazardous material; LN2 material will be shipped on dry ice unless otherwise requested: 
  
 £ 50.00 (fifty pounds) per each shipping box 
  
 Actual costs charged by third party shippers not included. 
  

 Page 8 of 9 

 Exhibit B 
  

Settlement Agreement 
  

 Page 9 of 9Cash Bonus Plans Available to Corporate Officers

 Exhibit 10.105 
  
 Synbiotics Corporation 2005 Cash Bonus Plans Available To Corporate Officers 
 Effective March 17, 2005 
  
 The officers of Synbiotics Corporation are eligible to participate in the following 2005 Synbiotics Corporation cash bonus plans: 
  
 2005 SYNBIOTICS CORPORATION EMPLOYEE PROFIT SHARING PLAN 
  
 Eligible Employees are full-time active employees of Synbiotics Corporation,
San Diego, California as of December 31, 2005. Employees hired in 2005 will be eligible on a prorated basis for the time in 2005 they were employed as full-time employees. Any employee that experiences a leave without pay status during the year will
be ineligible for the period of time they are unemployed. 
  
 The
total funds for the pool will be 5% of Operating Income of the San Diego business (non-consolidated) of Synbiotics Corporation for the one year period ending December 31, 2005. This pool will then be divided equally among all Eligible Employees
after the year-end result has been audited. 
  
 2005 SYNBIOTICS
CORPORATION OFFICER BONUS PLAN 
  
 Eligible officers are Keith
Butler, Clifford Frank and Kent Luther. 
  
 Budgeted 2005
Consolidated EBITDA is $2,198,000. 
  
 Based upon consolidated
audited results of Synbiotics Corporation for the twelve month period ending December 31, 2005, provided each of the above participants is still an employee of the company on December 31, 2005, the following amounts shall by pad to each
participant: 2% of the first $1,000,000 EBITDA in excess of $2,000,000 and 3% of EBITDA in excess of $3,000,000. An additional $10,000 will be paid to each participant should EBITDA exceed the above stated budgeted amount fro 2005. The above
consideration will be payable after the year-end result is audited. 
  
 Examples: 
  

						
	EBITDA

	  	Performance Bonus

	  	 Calculation

	£$2,000,000	  	$	0	  	 
	$2,650,000	  	$	23,000	  	($650,000 *2%) + $10,000
	$3,200,000	  	$	36,000	  	($1,000,000*2%)+($200,000*3%)+$10,000
	$4,350,000	  	$	70,500	  	($1,000,000*2%)+($1,350,000*3%)+$10,000

  
 Officers will be
notified of any cash bonuses earned via the form attached as Exhibit A. 

 Exhibit A 
  

Notification Of Bonus Earned Under 
 Synbiotics Corporation 2005 Cash Bonus Plans Available To Corporate Officers 
  
 Name:                                     
         
  
 You have earned
the following cash bonuses under the Synbiotics Corporation 2005 cash bonus plans in which you are eligible: 
  

					
			
	1)	  	2005 Synbiotics Corporation Employee Profit Sharing Plan:	  	$                        
			
	2)	  	2005 Synbiotics Corporation Officer Bonus Plan:	  	$                        

  
 These amounts will be
paid to you on or before                         , 2005. 
  

			
		
	By:	 	 
		
	Title:	 	 
		
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]